Debt-to-equity of Whitehawk Therapeutics, Inc. from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Whitehawk Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • Whitehawk Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 8.1%, a 68% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Whitehawk Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 8.1% -17% -68% 30 Sep 2025
Q2 2025 11% -13% -54% 30 Jun 2025
Q1 2025 17% -3.5% -17% 31 Mar 2025
Q4 2024 27% +8.3% +45% 31 Dec 2024
Q3 2024 25% +8.9% +54% 30 Sep 2024
Q2 2024 23% +7.7% +49% 30 Jun 2024
Q1 2024 20% +3.6% +22% 31 Mar 2024
Q4 2023 19% +2.8% +18% 31 Dec 2023
Q3 2023 17% +0.96% +6.2% 30 Sep 2023
Q2 2023 16% +0.98% +6.6% 30 Jun 2023
Q1 2023 16% +1.3% +8.6% 31 Mar 2023
Q4 2022 16% -1.7% -9.7% 31 Dec 2022
Q3 2022 16% -37% -70% 30 Sep 2022
Q2 2022 15% +69% 30 Jun 2022
Q1 2022 15% +72% 31 Mar 2022
Q4 2021 17% +80% 31 Dec 2021
Q3 2021 53% +72% 30 Sep 2021
Q2 2021 -54% -556% -111% 30 Jun 2021
Q1 2021 -57% -78% -372% 31 Mar 2021
Q4 2020 -63% -75% -628% 31 Dec 2020
Q3 2020 -20% -29% -322% 30 Sep 2020
Q2 2020 502% 30 Jun 2020
Q1 2020 21% 31 Mar 2020
Q4 2019 12% 31 Dec 2019
Q3 2019 8.9% 30 Sep 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.